336 results about "Ticagrelor" patented technology

The invention provides a preparation method of ticagrelor, belonging to the technical field of medicine manufacturing. According to the method, a compound VII is taken as a raw material, and the method comprises the steps of: carrying out a nucleophilic substitution reaction on the raw material to obtain a compound VI; hydrogenating the VI, removing carbamazepine (Cbz) protection to obtain a compound V; carrying out a reaction on the V and 4, 6-dichloro-2-(allyl sulfide)-5-amio-pyrimidine to obtain a compound IV; carrying out a reaction on the IV and nitrite of alkali metal to obtain a compound III; carrying out a reaction on the III and (1R, 2S)-2-(3, 4-difluoro phenyl) cyclopropylamine to obtain a compound II; and finally, removing protecting group of the II to obtain a compound I.

The invention provides a novel intermediate of ticagrelor or its salt. The novel intermediate is shown in the formula 5. In the formula 5, P1 represents a hydroxyl protecting group. The invention also provides a method for preparing ticagrelor from the novel intermediate shown in the formula 5. The method for preparing ticagrelor from the novel intermediate shown in the formula 5 has the advantages of simple processes, high yield and less three wastes, and can satisfy the demand of industrial production.

The invention provides a ticagrelor sustained-release tablet system and a preparation method of the ticagrelor sustained-release tablet system. The preparation method comprises the following steps of: firstly uniformly mixing 10-60% of ticagrelor, 5-60% of a filler and 5-60% of high molecular polymer in percentage by weight, adding a granulating solution to granulate; fully drying the obtained granules at a temperature of 50-60 DEG C, uniformly mixing the sieved granules with 0.25-10% of a lubricant and/or 0-10% of a flow aid, carrying out tabletting to obtain the ticagrelor matrix type sustained-release tablets, wherein the granulating solution is preferably water, an alcohol-water solution or absolute ethyl alcohol; the granule size of the ticagrelor is below 100 micrometers; and the content of the ticagrelor is 50-300mg in the preparation process. The ticagrelor matrix type sustained-release tablet system provided by the invention has the advantages that a patient can take the ticagrelor once a day to ensure that the drug dependence of the patient can be improved and the risk of myocardial infarction or apoplexy caused by acute thrombosis due to a dose of the ticagrelor missing of the patient is reduced.

The invention provides a novel preparation method which is easily industrially achieved and is simple and convenient to carry out and is established under a new intermediate. The invention relates to a novel preparation method of micromolecule anticoagulant Ticagrelor, and synchronously relates to an intermediate body for synthesizing the Ticagrelor and a preparation method of the intermediate. With the adoption of the synthesis method provided by the invention, the side reaction in the reaction process can be effectively reduced, the purity of the intermediate is improved, and the purifying way of the intermediate is simplified.

The invention relates to the medicine chemical synthesis field, and especially discloses a preparation method of a Ticagrelor intermediate. The preparation method comprises the following steps: 1) taking 3,4-difluorobenzaldehyde (I) as an initial raw material, reacting with a phosphorus ylide material liquid to obtain (E)-3-(3,4-difluorophenyl)-2-acrylic acid ester (II); 2) performing a Simons-Smith asymmetric cyproteronethe reaction on the (E)-3-(3,4-difluorophenyl)-2-acrylic acid ester (II) to obtain trans-(1R,2R)-2-(3,4-difluorophenyl) cyclopropanecarboxylic acid ester (III); 3) performing aminolysis on the trans-(1R,2R)-2-(3,4-difluorophenyl) cyclopropanecarboxylic acid ester to obtain trans-(1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxamide (IV); and 4) performing a Huffman rearrangement reaction on the trans-(1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxamide (IV) to obatain the Ticagrelor intermediate (V). The method of the invention has the advantages of simple process, convenient operation, mild reaction condition and easy control, low cost and easy acquisition of raw material, high product yield and product purity, and is adapted to large scale industrial production.

The invention discloses a method for preparing ticagrelor, which comprises the following steps of by taking 1-[(3aR,4S,6R,6aS)-[[2,2- dimethyl-tetralin-4H-cyclopentadiene-1,3-dioxo heterocyclelane-4-oxygroup] ethyl acetate-6-base]-5-amidogen-4-formamido-1,2,3- triazole(II) as the raw material, sequentially carrying out cyclizing, replacement, condensation and reduction reactions, and removing the protecting group, so as to prepare the ticagrelor. The method is concise, environment-friendly and economic, has high chemical and chirality purity, and provides the new preparation method of ticagrelor industrialized production.

The invention belongs to the field of analytical chemistry and in particular relates to a method for separating and measuring ticagrelor and a diastereoisomer of the ticagrelor. The method is characterized in that a chiral HPLC (High Performance Liquid Chromatography) column taking polysaccharide derivative as a filler is used and a mixed solution of lower paraffin hydrocarbon and low alcohol is used as a moving phase; according to the separating and detecting method, the ticagrelor and the diastereoisomer of the ticagrelor are effectively separated, and the mass of the ticagrelor can be effectively controlled. The method can be used for separating and detecting the ticagrelor and the diastereoisomer of the ticagrelor simply, rapidly and accurately.

The invention discloses a preparation method of ticagrelor. The preparation method comprises the following steps of: carrying out a cyclization reaction between 5-amino-1,4-di-substituted-1,2,3-triazole (II) and a sulfur-containing cyclizing agent (III), thereby obtaining 9-substituted-2-sulfo-6-oxo-8-azaguanine (IV), carrying out a substitution reaction between the intermediate (IV) and halogenated propane (V) to generate 9-substituted-2-propylthiol-6-oxo-8-azaguanine (VI), carrying out condensation between the intermediate (VI) and trans-(1R,2S)-2-(3,4-difluorophenyl) cyclopropylamine (VII) to generate 9-substituted-6-amino substituent-2-propylthiol-8-azaguanine (VIII), and depriving an idene acetone protecting group from the intermediate (VIII) to obtain the ticagrelor (I). The preparation method disclosed by the invention is simple in process, economic and environment-friendly, and high in chemical and chiral purity, and provides a new preparation way for industrial production of the ticagrelor.

The invention provides a slow/controlled-release preparation of ticagrelor. The slow/controlled-release preparation of ticagrelor is an oral drug. The slow/controlled-release preparation contains ticagrelor or its pharmaceutically acceptable salt. A mass percent of ticagrelor to controlled-release accessory materials is in a range of 1: 0.2 to 1: 20 and preferably, the mass percent is in a range of 1: 0.1 to 1: 10, and a proper amount of other accessory materials are used. The slow/controlled-release base comprises one or more of cellulose, cellulose derivatives, alginate, starch, starch derivatives, polypropylene resins, carboxyvinyl polymers and other controlled-release accessory materials. Compared with a fast-release preparation, the slow/controlled-release preparation of ticagrelor provides a ticagrelor slow/controlled-release preparation system, can be eaten by a patient once each day, can change drug compliance of patients, can reduce the risk of myocardial infarction or stroke caused by acute thrombosis caused by missing of ticagrelor, and provides the easily-prepared slow/controlled-release preparation of ticagrelor or its pharmaceutically acceptable salt.

The invention discloses ticagrelor tablets and a preparation method thereof and belongs to the technical field of medicines. According to the ticagrelor tablets disclosed by the invention, mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, croscarmellose sodium and magnesium stearate are selected as auxiliary materials and are compounded with the raw material medicine ticagrelor tablets so as to obtain the ticagrelor tablets, and each auxiliary material and the raw material medicine are synergetic in the defined amount range, so that the dissolution rate of the prepared ticagrelor tablets is higher than that of the conventional commercially available tablets. Moreover, the ticagrelor tablets have the same dissolution behavior as the commercially available medicines, the ticagrelor tablets have good absorption effects, and the bioavailability of the ticagrelor tablets is improved. The ticagrelor tablets disclosed by the invention are small in impurity content and are stable in performance under high-temperature illumination conditions. The method for preparing the ticagrelor tablets disclosed by the invention is simple in process flow, easy to operate and implement and suitable for industrial popularization and application.

The invention relates to a novel oral enteric preparation which is composed of 0.1-1000mg of Grel drugs, or medically acceptable salts, ester or derivatives, 37.5-325mg of aspirin and at least one medically acceptable load, wherein the Grel drugs, or medically acceptable salts, esters or derivatives are clopidogrel, prasugrel, brilinta, sarpogrelate, ozagrel, anagrelide, pamicogrel, or medically acceptable salts, ester or derivatives, preferably, clopidogrel sulfate. The oral enteric preparation is used for curing acute coronary syndrome (ACS), angor pectoris, stroke, myocardial infarction or cardia cerebrovascular diseases of patients. According to the oral enteric preparation, adverse reactions such as functional gastrointestinal disorders, nausea, vomit, gastritis, concealed hemorrhage, ulcer exacerbation and gastrointestinal bleeding caused by strong stimulus of aspirin to stomach can be avoided.

The invention belongs to the technical field of gene engineering and enzyme engineering, and particularly relates to a carbonyl reductase mutant and application thereof. The carbonyl reductase ChKRED20 can realize asymmetric reduction of 2-chloro-1-(3,4-difluoro-phenyl)-ethanone to obtain a Ticagrelor intermediate (S)-2-chloro-1-(3,4-difluorophenyl)ethanol (the e. e. value is larger than 99%), and the error-prone PCR technology and the single-point saturation mutagenesis technology are utilized to realize orthogenesis of enzyme molecules to obtain 11 mutants of which the enzyme activities are improved by 1.6-10 times, so that the application potential in biocatalysis is shown.

A preparation method of Ticagrelor comprises the following steps: (1) dissolving a compound shown in formula M-1 into methylbenzene and acetic acid, dropwise adding an aqueous solution of sodium nitrite, and keeping the temperature at 30DEG C or below to obtain a compound shown in formula M-2; (2) performing acetonitrile beating treatment on a compound shown in formula SM1, adding the treated compound shown in formula SM1 into an aqueous solution of potassium carbonate, under the protection of inert gas, adding the aqueous solution of potassium carbonate into the compound shown in formula M-2, which is obtained in step (1), and performing a condensation reaction to obtain a compound shown in formula M-3; (3) under the protection of inert gas, hydrolyzing the compound shown in formula M-3, which is obtained in step (2), into a mixed solution of concentrated hydrochloric acid and methyl alcohol to obtain coarse Ticagrelor shown in formula TGRL; and (4) recrystallizing the coarse Ticagrelor obtained in step (3) with ethyl acetate-isooctane to obtain high-purity Ticagrelor. Ticagrelor prepared according to the preparation method provided by the invention is up to the purity above 99.50% and contains 0.1wt% of TGRL-A to TGRL-D and less than 0.5wt% of total impurities.

The invention discloses a preparation method of ticagrelor. The preparation method comprises the following steps of: carrying out cyclization reaction between 5-amido-1,4-bis-substituent group-1,2,3-triazole (II) and a sulfur-containing cyclizing agent (III) to obtain 9-substitution-2-sulfo-6-oxo-8-azapurine (IV); carrying out substitution reaction between an intermediate (IV) and halogenated propane (V) to generate 9-substitution-2-propyl sulfydryl-6-oxo-8-azapurine (VI); chloridizing an intermediate (VI), and carrying out amination reaction between the intermediate (VI) and trans-(1R, 2S)-2-(3,4-difluorophenyl) rolicyprine (VII) to generate 9-substitution-6-amido substituendum-2-propyl sulfydryl-8-azapurine (VIII); and removing the propylidene acetonyl out of an intermediate (VIII) to obtain ticagrelor (I). The preparation method has the advantages of simple process and high chemical and chiral purity and provides a new preparation way for the industrialization of the ticagrelor.

The invention discloses a ticagrelor impurity preparation method, wherein 4,6-dichloro-2-(propylthio)-5-aminopyrimidine and (1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine(R)-mandelate are used as starting raw materials, and are subjected to a nucleophilic substitution reaction under alkaline conditions, a diazotization ring-closing reaction is performed to prepare a triazole intermediate, the triazole intermediate and 2-(((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH- cyclopentyl[d][1,3]dioxa-4-yl)oxy)ethanol L-(+)-tartrate are subjected to C-N coupling to obtain a ticagrelor impurity E,and the impurity E is hydrolyzed under acidic conditions to remove acetonylidene protection so as to obtain an impurity A. According to the present invention, the preparation method has characteristics of short synthesis route, simple operation and high product purity, and the obtained target product can be used as the impurity reference substance for controlling the purity of the ticagrelor raw materials or preparations.

The invention discloses a synthetic method for an intermediate compound (I) of ticagrelor and a mandelate compound(VI) thereof. Asymmetric reduction is carried out by the enzymic method; the synthetic method has the advantages of simple operation, mild reaction condition, little pollution, high yield of the product, good optical purity, thus the synthetic method is suitable for large-scale production; the energy consumption and the discharge of organic waste-water are greatly reduced, and requirements of large-scale industrial production are met well.

The invention discloses a 5-amino-1,4-disubstituent-1,2,3-triazole and a preparation method thereof. The compound (I) is a key intermediate for preparing medicines with a 1,2,3-triazole structure, such as ticagrelor. The preparation method for 5-amino-1,4-disubstituent-1,2,3-triazole comprises the following step of: performing cyclization reaction on an azide (II) with a cyano derivative (III) to obtain 5-amino-1,4-disubstituent-1,2,3-triazole. The preparation method is easily-available in raw materials, moderate in conditions, and high in yield.

The invention provides a ticagrelor and aspirin compound tablet and a preparation method thereof. The ticagrelor and aspirin compound tablet is prepared from an anti-sticking agent formed by stearic acid and aerosil in a mass ratio of (5-30) to (1-3). The ticagrelor and aspirin compound tablet has high stability, is easy to store, is less in adhesion between the tablet and a tableting device in a tableting process, and has a high tableting success rate.

The invention discloses a preparation method of a ticagrelor intermediate. The preparation method comprises the following steps: (1) reacting a compound in formula (8) with a compound in formula (9), so as to obtain a compound in formula (10); (2) carrying out ester group reduction on the compound in formula (10), so as to obtain a compound in formula (11); (3) desorbing benzyl protection of the compound in formula (11), so as to obtain a compound in formula (2). A synthetic method and a path provided by the invention have the advantages of short reaction step, high atom economy and low cost, and are environmentally friendly and suitable for industrial production. General formulas are as follows (as shown in the specification).

The invention relates to a slow-release preparation of ticagrelor. Specifically, the slow-release preparation of the ticagrelor, provided by the invention, is suitable for being orally taken one timeevery day; meanwhile, a rapid drug releasing effect can be realized after tablets are damaged. The releasing tablets which are administrated one time every day can reduce the number of times of oral administration, so that the oral drug taking compliance of patients can be improved and risks that myocardial infarction or stroke is caused when acute thrombus formation is caused by the fact that thepatients forget to orally take the ticagrelor are reduced; meanwhile, when the tablets provided by the invention are orally taken for the first time, the tablets can be opened to meet the requirementof giving a load dosage to the patients, so as to rapidly take effect.